CROSSWICKS, N.J.--(BUSINESS WIRE)--The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year’s American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
